Novo Nordisk licenses potential once-weekly obesity pill from Hengrui in $2.6B deal
Novo Nordisk will pay China’s Jiangsu Hengrui Pharmaceuticals $300 million upfront to license HRS-1596, a GLP-1/GIP dual receptor agonist for obesity, type 2 diabetes and other metabolic diseases. The package can reach $2.6 billion via milestones—Hengrui’s filing cites up to $2.3 billion in milestones—plus royalties on net sales where Novo holds rights. Novo gets exclusive development, manufacturing and commercialization outside mainland China, Hong Kong, Macau and Taiwan; Hengrui keeps those markets. Hengrui has China approval to start Phase 1. Novo said the candidate could be a once-weekly oral drug that would “substantially reduce dosing frequency and improve convenience compared with current offerings.” Chief scientific officer Martin Holst Lange said the move advances Novo’s obesity, diabetes and cardiometabolic pipeline. A Novo spokesperson told Reuters global trials are planned but gave no timelines. Closing is expected in Q4 2026, pending U.S. antitrust clearance and other conditions. Contested: no material factual disputes found; outlets differ only on Hengrui’s same-day Hong Kong rise (about 1.5% at HK$45.44 versus about 3%) and one source had Novo shares down 0.30%. Earlier in September 2026 Novo agreed to pay up to $1.3 billion for Nanexa delivery technology; earlier in 2026 Hengrui signed a Bristol Myers Squibb deal worth up to an estimated $15.2 billion.




